Quantitative Proteomics Services

Please see our Instructions for Sending Samples resource page.

Most of our arrays are compatible with any biological fluid. This includes cell culture media, cell lysates, tissue lysates, and all clarified body fluids (serum, plasma, urine, cerebrospinal fluid, BAL, saliva, tears, etc.)

Quantitative Proteomics has a 5-sample minimum and Discovery Proteomics has a 4-sample minimum. Talk to a specialist if your study is smaller and we’ll help you find the best option.

Standard turnaround for our proteomic services is 6–8 weeks from receipt of samples.

A complete data package: raw data (spot-to-spot OD), background subtraction, normalization steps, and standard curves where applicable. These bioinformatics-ready outputs are delivered in both Excel and PDF formats, and every report is analyzed by a PhD scientist.

Quantibody® is an array-based multiplex ELISA system for simultaneous quantitative measurement of multiple cytokines, growth factors, proteases, soluble receptors, and other proteins in a wide variety of sample types. Quantibody combines the high specificity and sensitivity of ELISA with the high throughput of the glass chip-based array.

They are complementary methods. Our arrays are affinity-based, using a defined menu of antibodies with ELISA-grade sensitivity (down to pg/mL) from microliter-scale samples; no fractionation or enrichment is required. Mass spectrometry excels at unbiased identification; antibody arrays excel at sensitive, reproducible detection of low-abundance signaling proteins. Many labs use MS to discover and our platforms to quantify and validate.

Yes. This is one of the biggest advantages of working with a single partner: cast a wide net on the Discovery platform, then move your top candidates onto Quantibody for absolute, ELISA-grade quantification, without onboarding a new vendor or reformatting your samples.

Yes. Beyond off-the-shelf panels, we build custom arrays from our validated antibody-pair catalog to match your target list and study design.

Our main laboratory is a high-complexity CLIA lab accredited to ISO 13485:2016 and ISO 17025:2017 and operates under cGMP, with GLP-compliant, in-house-validated protocols.

We can help you identify potential biomarkers for disease identification, management and drug development. Our service can help you discover the molecular mechanisms involved in disease processes and the ways therapeutics act. We can profile expression patterns inherent in a given disease state to help develop better diagnostics.